Related Experiment Video
Updated: Jan 19, 2026
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Atrial fibrillation with percutaneous coronary intervention: Navigating the minefield of antithrombotic therapies
Kevin R Bainey1, João Morais2, Uwe Zeymer3
1Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
Insights
For atrial fibrillation (AF) patients needing percutaneous coronary intervention (PCI), dual therapy (oral anticoagulant + 1 antiplatelet) is preferred. Triple therapy is limited, and OAC monotherapy is recommended long-term post-PCI.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Guidelines
Background:
- Atrial fibrillation (AF) is a common arrhythmia and significant stroke risk factor.
- Oral anticoagulant (OAC) therapy reduces stroke risk.
- Percutaneous coronary intervention (PCI) in AF patients requires combined antithrombotic therapy to prevent coronary events.
Purpose of the Study:
- To review current therapeutic strategies for AF patients undergoing PCI.
- To compare international guidelines on antithrombotic therapy in this population.
- To identify consensus points and areas of clinical debate regarding treatment duration and combinations.
Main Methods:
- Review of contemporary therapeutic options for AF patients undergoing PCI.
- Comparative analysis of current international clinical guidelines.
- Synthesis of evidence regarding antithrombotic therapy combinations and durations.
Main Results:
- Recent evidence favors dual antithrombotic therapy (OAC plus one antiplatelet).
- Triple antithrombotic therapy is recommended only when ischemic risk outweighs bleeding risk, for limited durations.
- Lifelong OAC monotherapy is recommended for stable patients 12 months post-PCI.
Conclusions:
- Guidelines show consensus on preferred dual antithrombotic therapy post-PCI for AF patients.
- Short-term triple therapy is reserved for high-risk patients.
- Long-term OAC monotherapy is the recommended strategy for stable patients after the initial period.
Abstract:
This review aims to provide insights into contemporary therapeutic options for the treatment of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) and compares current international guidelines. AF is a common cardiac arrhythmia and a major risk factor for stroke. The risk of stroke can be reduced with the use of oral anticoagulant (OAC) therapy. However, for patients with AF, PCI necessitates the use of combined antithrombotic therapies (OAC and antiplatelet therapies) to reduce thrombotic coronary complications. Optimal combinations and durations of OAC and/or antiplatelet therapy remains an area of clinical debate. Nuances exist within the current guidelines regarding duration and combination of antithrombotic therapy for AF patients requiring PCI. However, consensus was found across the following key points: (i) recent evidence supports a preferred role for a dual antithrombotic approach (OAC plus 1 antiplatelet); (ii) limited use of triple antithrombotic therapy is recommended across all guidelines for patients where the ischemic risk outweighs the risk of bleeding, with the duration to be kept as short as possible; and (iii) lifelong management using monotherapy with an OAC from 12 months post PCI is recommended for stable patients across all guidelines.
Related Concept Videos
11:21Robotic Ablation of Atrial Fibrillation
05:12Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
08:56Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:05Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
09:17High-Resolution Endocardial and Epicardial Optical Mapping in a Sheep Model of Stretch-Induced Atrial Fibrillation
04:58Reduced Procedure Time and Variability with Active Esophageal Cooling During Radiofrequency Ablation for Atrial Fibrillation